These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1610 related articles for article (PubMed ID: 17605655)

  • 1. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
    Koledova VV; Khalil RA
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):777-89. PubMed ID: 17605655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease.
    Ross RL; Serock MR; Khalil RA
    Curr Cardiol Rev; 2008 Nov; 4(4):309-22. PubMed ID: 20066139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex hormones, vascular function and the outcome of hormone replacement therapy in cardiovascular disease.
    Khalil RA
    Future Cardiol; 2007 May; 3(3):283-300. PubMed ID: 19804220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?
    Rosano GM; Vitale C; Fini M
    Ann N Y Acad Sci; 2006 Dec; 1092():341-8. PubMed ID: 17308159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hormone replacement therapy of menopause, heart and blood vessels].
    Kuttenn F; Gerson M
    Arch Mal Coeur Vaiss; 2001 Jul; 94(7):685-9. PubMed ID: 11494629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women.
    Ho JY; Chen MJ; Sheu WH; Yi YC; Tsai AC; Guu HF; Ho ES
    Hum Reprod; 2006 Oct; 21(10):2715-20. PubMed ID: 16807281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk.
    Silvestri A; Gambacciani M; Vitale C; Monteleone P; Ciaponi M; Fini M; Genazzani AR; Mercuro G; Rosano GM
    Maturitas; 2005 Apr; 50(4):305-11. PubMed ID: 15780531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.
    Khalil RA
    Biochem Pharmacol; 2013 Dec; 86(12):1627-42. PubMed ID: 24099797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex steroids and vascular responses in hypertension and aging.
    Qiao X; McConnell KR; Khalil RA
    Gend Med; 2008; 5 Suppl A():S46-64. PubMed ID: 18395683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen.
    Dubey RK; Imthurn B; Barton M; Jackson EK
    Cardiovasc Res; 2005 May; 66(2):295-306. PubMed ID: 15820198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone replacement therapy in postmenopausal women.
    Yasui T; Uemura H; Takikawa M; Irahara M
    J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing hormonal signaling for cardioprotection.
    Ballard VL; Edelberg JM
    Sci Aging Knowledge Environ; 2005 Dec; 2005(51):re6. PubMed ID: 16371658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Stramba-Badiale M
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):303-9. PubMed ID: 19430340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M; Simoncini T; Fuller S; Genazzani AR
    Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI.
    Clanget C; Hinke V; Lange S; Fricke R; Botko R; Pfeilschifter J
    Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):529-33. PubMed ID: 16235155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone replacement therapy in postmenopausal women.
    Prelevic GM; Kocjan T; Markou A
    Minerva Endocrinol; 2005 Mar; 30(1):27-36. PubMed ID: 15877011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause.
    Serock MR; Wells AK; Khalil RA
    Recent Pat Cardiovasc Drug Discov; 2008 Nov; 3(3):165-86. PubMed ID: 18991792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 81.